King & Wood Mallesons 28F, China Resources Tower 2666 Keyuan South Road, Nanshan District Shenzhen, Guangdong, 518052, PRC T +86 755 2216 3333 F +86 755 2216 3380 www.kingandwood.com
To: Shenzhen Salubris Pharmaceuticals Co., Ltd.
King & Wood Mallesons (Shenzhen) (hereinafter referred to as "the Firm") has been retained by Shenzhen Salubris Pharmaceuticals Co., Ltd. (hereinafter referred to as "the Company") to issue this Legal Opinion on the 2025 Annual General Meeting of Shareholders (hereinafter referred to as "the AGM").
In connection with this Legal Opinion, the Firm has reviewed the following documents provided by the Company, including but not limited to:
- The Articles of Association of Shenzhen Salubris Pharmaceuticals Co., Ltd. (hereinafter referred to as "the Articles of Association"), as deliberated and approved by the Company's 2025 First Extraordinary General Meeting of Shareholders;
- The "Resolution Announcement of the 18th Meeting of the Sixth Board of Directors of Shenzhen Salubris Pharmaceuticals Co., Ltd." published by the Company on April 21, 2026, on designated information disclosure media such as CNIInfo.com and Securities Times, as well as the Shenzhen Stock Exchange website;
- The "Notice of the 2025 Annual General Meeting of Shareholders of Shenzhen Salubris Pharmaceuticals Co., Ltd." published by the Company on April 21, 2026, on designated information disclosure media such as CNIInfo.com and Securities Times, as well as the Shenzhen Stock Exchange website (Announcement No.: 2026-036, hereinafter referred to as the "Notice of the AGM");
- The shareholder register of the Company for the stock registration date of this AGM;
- The attendance registration records and supporting documents of shareholders present at the on-site meeting;
- Statistical results of the online voting for this AGM provided by Shenzhen Securities Information Co., Ltd.;
- Announcements regarding the proposals for this AGM and related matters;
- Other meeting documents related to this AGM.